Cover Image

Hematopoietic SCT in Europe: data and trends in 2011

In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin’s lymphoma, Hodgkin’s lymph...

Full description

Saved in:
Bibliographic Details
Main Authors: Passweg, Jakob R. (Author) , Baldomero, H. (Author) , Bregni, M. (Author) , Cesaro, S. (Author) , Dreger, Peter (Author) , Duarte, R. F. (Author) , Falkenburg, J. H. F. (Author) , Kröger, N. (Author) , Farge-Bancel, D. (Author) , Bobby Gaspar, H. (Author) , Marsh, J. (Author) , Mohty, M. (Author) , Peters, C. (Author) , Sureda, A. (Author) , Velardi, A. (Author) , Ruiz de Elvira, C. (Author) , Madrigal, A. (Author)
Format: Article (Journal)
Language:English
Published: 15 April 2013
In: Bone marrow transplantation
Year: 2013, Volume: 48, Issue: 9, Pages: 1161-1167
ISSN:1476-5365
DOI:10.1038/bmt.2013.51
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2013.51
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt201351
Get full text
Author Notes:J.R. Passweg, H. Baldomero, M. Bregni, S. Cesaro, P. Dreger, R. F. Duarte, J.H.F. Falkenburg, N. Kröger, D. Farge-Bancel, H. Bobby Gaspar, J. Marsh, M. Mohty, C. Peters, A. Sureda, A. Velardi, C. Ruiz de Elvira and A. Madrigal
Description
Summary:In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, plasma cell disorders; 18 433 (57%; 12% allogeneic); solid tumours; 1573 (5%; 5% allogeneic); and non-malignant disorders; 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling donors (54% versus 39%); proportion of peripheral blood as stem cell source was 99% for autologous and 73% for allogeneic HSCT. Cord blood was only used in allogeneic transplants (6% of total). In the past 10 years, the overall number of transplants has increased by 53%. Allogeneic HSCT have doubled (from 7272 to 14 549) while, autologous have increased by 32% and continue to increase by about 1100 HSCT per year since 2001. In the past 2 years, an increase of >2000 HSCT per year was seen. Transplant activity is shown by team size. For allogeneic HSCT, we show use of reduced-intensity conditioning versus myeloablative conditioning across Europe and use of post-transplant donor lymphocyte infusions with considerable variation across different countries.
Item Description:Gesehen am 20.12.2021
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2013.51

Similar Items